{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-25-000033","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.622785+00:00","generated_at":"2026-05-22T06:19:58.970227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ligand Q1 revenue up 46% to $45.3M; core adjusted EPS $1.33; reaffirms FY guidance","bullets":["Total revenues $45.3M (+46% YoY), royalties $27.5M (+44%), Captisol $13.5M (+47%).","GAAP net loss $42.5M ($2.21/sh) includes $44.3M one-time R&D charge for Castle Creek; core adjusted net income $26.6M ($1.33/sh).","Reaffirms FY2025 guidance: revenue $180-200M, adjusted EPS $6.00-$6.25.","Pelthos to merge with Channel Therapeutics (NYSE: PTHS) backed by $50M capital; expected close summer 2025.","Led $50M of $75M Castle Creek royalty financing for D-Fi Phase 3; net mid-single digit royalty."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-25-000033","json":"https://secwatch.observer/filing/0000886163-25-000033.json","markdown":"https://secwatch.observer/filing/0000886163-25-000033.md","text":"https://secwatch.observer/filing/0000886163-25-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000033/0000886163-25-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000033/lgnd-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:19:58.970227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}